Next Article in Journal
Inducible Nitric Oxide Synthase (iNOS) Mediates Vascular Endothelial Cell Apoptosis in Grass Carp Reovirus (GCRV)-Induced Hemorrhage
Next Article in Special Issue
Pseudoxanthoma Elasticum, Kidney Stones and Pyrophosphate: From a Rare Disease to Urolithiasis and Vascular Calcifications
Previous Article in Journal
Genome- and Transcriptome-Wide Characterization of bZIP Gene Family Identifies Potential Members Involved in Abiotic Stress Response and Anthocyanin Biosynthesis in Radish (Raphanus sativus L.)
Previous Article in Special Issue
Proteomic Analysis of Urinary Extracellular Vesicles Reveals a Role for the Complement System in Medullary Sponge Kidney Disease
Open AccessReview

Complement and Complement Targeting Therapies in Glomerular Diseases

1
Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, 1 Levy Place, New York, NY 10029, USA
2
Renal Unit, Department of Medicine, University/Hospital of Verona, 37126 Verona, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(24), 6336; https://doi.org/10.3390/ijms20246336
Received: 14 November 2019 / Accepted: 10 December 2019 / Published: 16 December 2019
The complement cascade is part of the innate immune system whose actions protect hosts from pathogens. Recent research shows complement involvement in a wide spectrum of renal disease pathogenesis including antibody-related glomerulopathies and non-antibody-mediated kidney diseases, such as C3 glomerular disease, atypical hemolytic uremic syndrome, and focal segmental glomerulosclerosis. A pivotal role in renal pathogenesis makes targeting complement activation an attractive therapeutic strategy. Over the last decade, a growing number of anti-complement agents have been developed; some are approved for clinical use and many others are in the pipeline. Herein, we review the pathways of complement activation and regulation, illustrate its role instigating or amplifying glomerular injury, and discuss the most promising novel complement-targeting therapies. View Full-Text
Keywords: complement; alternative complement pathway; complement-targeting therapies; C3 glomerulopathy; hemolytic uremic syndrome; focal segmental glomerulosclerosis complement; alternative complement pathway; complement-targeting therapies; C3 glomerulopathy; hemolytic uremic syndrome; focal segmental glomerulosclerosis
Show Figures

Figure 1

MDPI and ACS Style

Andrighetto, S.; Leventhal, J.; Zaza, G.; Cravedi, P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int. J. Mol. Sci. 2019, 20, 6336.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop